Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
申请人:Novartis AG
公开号:US09199973B2
公开(公告)日:2015-12-01
A pharmaceutical formulation comprising the compound of formula
一种药物制剂,包括以下公式的化合物
Anilinoquinazolines as protein tyrosine kinase inhibitors
申请人:Cockerill George Stuart
公开号:US06933299B1
公开(公告)日:2005-08-23
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
Anilinoquinazaolines as protein tyrosine kianse inhibitors
申请人:Cockerill Stuart George
公开号:US20050143401A1
公开(公告)日:2005-06-30
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.
A process for the preparation of a compound of formula (I)
comprising the steps:
(a) reacting a compound of formula (II)
wherein L and L′ are suitable leaving groups, with a compound of formula (III)
UNH
2
(III)
to prepare a compound of formula (IV)
and subsequently (b) substituting the group R
1
by replacement of the leaving group L′.